Search research articles
Contact Us
Filters
Showing results (481-490 of 706) with videos related to
Page
of 71
Sort By:
Lancet (London, England)
|
March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad, Christopher P Cannon, William C Cushman, et al.
Diabetes, Obesity & Metabolism
|
May 22, 2020
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial
Clare Arnott, Yuli Huang, Brendon L Neuen, et al.
The American Journal of Cardiology
|
August 30, 2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
Emmanouil S Brilakis, James A de Lemos, Christopher P Cannon, et al.
JAMA Cardiology
|
March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study
Eric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Clinical Cardiology
|
October 10, 2019
Interleukin-18 in patients with acute coronary syndromes
Axel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The New England Journal of Medicine
|
November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Christopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Circulation
|
February 6, 2004
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial
Marc S Sabatine, David A Morrow, Robert P Giugliano, et al.
Lancet (London, England)
|
November 23, 2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P Cannon, Sean P Curtis, Garret A FitzGerald, et al.
The American Journal of Medicine
|
November 30, 2014
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease
Dharam J Kumbhani, Gregg C Fonarow, Christopher P Cannon, et al.
Critical Pathways in Cardiology
|
March 5, 2009
Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative
Charles V Pollack, Judd E Hollander, Anita Y Chen, et al.
Page
of 71
Search research articles
Search
Showing results (481-490 of 706) with videos related to
Sort By:
Page
of 71
Lancet (London, England)
|
March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad, Christopher P Cannon, William C Cushman, et al.
Diabetes, Obesity & Metabolism
|
May 22, 2020
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial
Clare Arnott, Yuli Huang, Brendon L Neuen, et al.
The American Journal of Cardiology
|
August 30, 2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
Emmanouil S Brilakis, James A de Lemos, Christopher P Cannon, et al.
JAMA Cardiology
|
March 16, 2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study
Eric A Secemsky, Robert W Yeh, Dean J Kereiakes, et al.
Clinical Cardiology
|
October 10, 2019
Interleukin-18 in patients with acute coronary syndromes
Axel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The New England Journal of Medicine
|
November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Christopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Circulation
|
February 6, 2004
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial
Marc S Sabatine, David A Morrow, Robert P Giugliano, et al.
Lancet (London, England)
|
November 23, 2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P Cannon, Sean P Curtis, Garret A FitzGerald, et al.
The American Journal of Medicine
|
November 30, 2014
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease
Dharam J Kumbhani, Gregg C Fonarow, Christopher P Cannon, et al.
Critical Pathways in Cardiology
|
March 5, 2009
Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative
Charles V Pollack, Judd E Hollander, Anita Y Chen, et al.
Page
of 71